TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39375179
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (400 mcg) and vitamin B supplementation for 3 months
Study: 39375634
Drug: Vestibular socket
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular socket therapy (VST) in infected sockets (group I)
Study: 39375634
Drug: Vestibular socket
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular socket therapy (VST) in non-infected sockets (group N)
Study: 39375710
Drug: Standard SafeCare
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard SafeCare (active treatment control); n=25
Study: 39375869
Drug: Dapagliflozin/linagliptin fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin/linagliptin fixed-dose combination (FDC [AJU-A51]) 10/5 mg/day (n=117)
Study: 39375869
Drug: Linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 5 mg plus placebo (n=118)
Study: 39375952
Drug: ABL001/CTX-009 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABL001/CTX-009 (10 mg/kg every other week)
Study: 39375952
Drug: ABL001/CTX-009 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABL001/CTX-009 (15 mg/kg every three weeks)
Study: 39375952
Drug: Weight-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based dosing
Study: 39376152
Drug: LEAP! Rx
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEAP! Rx (exercise and monthly brain health education)
Study: 39376771
Drug: Lidocaine 2.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2.0% infusion
Study: 39376771
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.9% infusion
Study: 39376791
Drug: Hypotonic fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic fluids (NaCl <130 mmol/L)
Study: 39376791
Drug: Isotonic fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic fluids (NaCl = 130-154 mmol/L)
Study: 39376864
Drug: Ethos OART
Normalized name: isostearyl ethylimidazolinium ethosulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethos OART platform delivering multi-site pulsed hypofractionated radiotherapy (40 Gy in 5 fractions) in combination with standard of care (SOC) chemoimmunotherapy.
Study: 39377148
Drug: Crushed ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crushed ticagrelor administered via nasogastric tube
Study: 39377880
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks for up to 35 treatments (~ 2 years)
Study: 39377970
Drug: no redifferentiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: no redifferentiation therapy
Study: 39378042
Drug: Tegoprazan 50
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 50 mg once daily
Study: 39378079
Drug: Ophthalmic acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic acupuncture with 'De Qi' sensation
Study: 39378080
Drug: Adaptive messaging
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive messaging group receiving text messages selected by a reinforcement learning algorithm daily
Study: 39378080
Drug: Random messaging
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random messaging group receiving randomly selected feedback and motivational text messages daily
Study: 39378080
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving a weekly mood monitoring message
Study: 39378281
Drug: 4-week loading
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week loading dose of 300 mg clofazimine once daily
Study: 39378281
Drug: 6-week loading
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week loading dose regimen
Study: 39378326
Drug: IM20×3 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM20×3 group (3 standard doses of 20 μg at 0-1-6 months)
Study: 39378326
Drug: IM20×4 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM20×4 group (4 standard doses of 20 μg at 0-1-2-6 months)
Study: 39378326
Drug: IM60×4 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM60×4 group (4 triple doses of 60 μg at 0-1-2-6 months)
Study: 39378423
Drug: Innovative technologies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovative technologies and treatment pathways
Study: 39379403
Drug: Viltolarsen 80
Normalized name: Viltolarsen
DrugBank: Viltolarsen (DB15005)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Viltolarsen 80 mg/kg intravenous once weekly for 48 weeks
Study: 39379540
Drug: Peroral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroral antibiotics (3-day course)
Study: 39379672
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mFRI and urinary injury biomarkers (uNAG or uNGAL)
Study: 39379797
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment (low-fat diet and lifestyle modification)
Study: 39379845
Drug: iCBT Shyness
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCBT Shyness Program (internet-delivered cognitive-behavioral therapy)
Study: 39379877
Drug: Suicide Attempts
Normalized name: modified Ankara virus-mediated suicide gene delivery vector TG4023
DrugBank: TG4023 (DB06108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suicide Attempts Multi-component Intervention Treatment (SAMIT) - 8 sessions of individual psychotherapy combining Dialectical Behaviour Therapy (DBT), Mentalization-Based Therapy (MBT), and Narrative approaches.
Study: 39379877
Drug: Treatment-as-usual intervention
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual intervention (TAU)
Study: 39379885
Drug: Treatment difference
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment difference between BTC and NLED
Study: 39379931
Drug: Lazertinib 240
Normalized name: lazertinib 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazertinib 240 mg/day
Study: 39380086
Drug: Community-wide mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-wide mass drug administration (cMDA) with 400 mg albendazole
Study: 39380954
Drug: Patient-specific dosimetry
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-specific dosimetry for DTC patients receiving radioiodine (RAI) therapy
Study: 39380967
Drug: Pyrotinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib (400 mg once daily) and capecitabine (1000 mg/m2)
Study: 39381777
Drug: Multimodal sensor-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal sensor-based eHealth intervention during 14 video sessions of cognitive-behavioral therapy (CBT)
Study: 39381863
Drug: Pegunigalsidase alfa
Normalized name: Pegunigalsidase alfa
DrugBank: Pegunigalsidase alfa (DB14992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegunigalsidase alfa 2 mg/kg every 4 weeks for 52 weeks
Study: 39382244
Drug: Remote daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote daily multidisciplinary rounds led by a board-certified intensivist through telemedicine, monthly audit and feedback meetings, provision of evidence-based clinical protocols.
Study: 39382244
Drug: Telemedicine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine intervention (daily multidisciplinary rounds).
Study: 39382241
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (transfusion triggered by hemoglobin <9 g/dL; n=408)
Study: 39382241
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (transfusion triggered by hemoglobin <7 g/dL; n=442)
Study: 39382446
Drug: First-line anti-angiogenesis
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line anti-angiogenesis therapy
Study: 39382446
Drug: Second-line anti-angiogenesis
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line anti-angiogenesis therapy
Study: 39382587
Drug: Control (G-C)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (G-C)
Study: 39383026
Drug: Preoperative acupuncture;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative acupuncture; details on dosage and duration not available
Study: 39383382
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma and standard treatment
Study: 39383612
Drug: Second-line immunosuppressants
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line immunosuppressants (SLI)
Study: 39383771
Drug: naporafenib plus
Normalized name: Naporafenib
DrugBank: Naporafenib (DB18865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: naporafenib plus rineterkib (naporafenib 400 mg BID, rineterkib 200 mg QD)
Study: 39383771
Drug: naporafenib plus
Normalized name: Naporafenib
DrugBank: Naporafenib (DB18865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: naporafenib plus trametinib (naporafenib 200 mg BID, trametinib 1 mg QD)
Study: 39383771
Drug: naporafenib plus
Normalized name: Naporafenib
DrugBank: Naporafenib (DB18865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: naporafenib plus trametinib (naporafenib 400 mg BID, trametinib 0.5 mg QD)
Study: 39384067
Drug: Cendakimab 360
Normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cendakimab 360 mg once weekly for 48 weeks
Study: 39384067
Drug: Cendakimab 360
Normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cendakimab 360 mg once weekly for 24 weeks followed by cendakimab 360 mg every other week for 24 weeks (with matching placebo on alternative weeks)
Study: 39384067
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once weekly for 48 weeks
Study: 39384087
Drug: Benzoate 1000
Normalized name: benzoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzoate 1000 mg/day
Study: 39384087
Drug: Benzoate 500
Normalized name: aminobenzoate 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzoate 500 mg/day
Study: 39384087
Drug: Benzoate 750
Normalized name: imidazole-2-hydroxybenzoate 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzoate 750 mg/day
Study: 39384194
Drug: BMS-986156 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986156 (30 mg) with ipilimumab (3 mg/kg)
Study: 39384194
Drug: BMS-986156 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986156 (100 mg) with ipilimumab (3 mg/kg)
Study: 39384194
Drug: BMS-986156 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986156 (30 mg) with nivolumab (480 mg) and SABR
Study: 39384241
Drug: CAS+IMD 1200
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAS+IMD 1200 mg
Study: 39384241
Drug: CAS+IMD 2400
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAS+IMD 2400 mg
Study: 39384241
Drug: CAS+IMD (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAS+IMD (1200 mg or 2400 mg)
Study: 39384342
Drug: eGFR <
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR < 60 mL/min/1.73m²
Study: 39384342
Drug: eGFR <
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR < 90 mL/min/1.73m²
Study: 39384451
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg b.i.d.) + Abiraterone (1000 mg o.d.) + Prednisone (5 mg b.i.d.)
Study: 39384451
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Abiraterone (1000 mg o.d.) + Prednisone (5 mg b.i.d.)
Study: 39384609
Drug: MGTA-145 (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGTA-145 (0.03 mg/kg) intravenously with plerixafor subcutaneously
Study: 39384614
Drug: Intranasal human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal human milk (IHM) therapy
Study: 39384712
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg/day) with standard medical therapy (Group A)
Study: 39384712
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with standard medical therapy (Group B)
Study: 39385217
Drug: OD(-) group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OD(-) group (withdrawal of life-sustaining therapies without planned organ donation)
Study: 39385217
Drug: OD(+) group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OD(+) group (withdrawal of life-sustaining therapies with planned organ donation)
Study: 39385279
Drug: Concussion-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concussion-focused cognitive behavioral therapy (cf-CBT)
Study: 39385279
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cf-CBT, PST, and CM
Study: 39385327
Drug: Abemaciclib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib plus non-steroidal aromatase inhibitor (anastrozole or letrozole)
Study: 39385523
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel 1.62% (40.5 mg/day for 16 weeks)
Study: 39385523
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel 1.62%
Study: 39385595
Drug: Citrulline Malate
Normalized name: CITRULLINE MALATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrulline Malate (6 g)
Study: 39385595
Drug: Placebo (6 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 g of corn starch)
Study: 39385752
Drug: Hexavalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent vaccine (DTaP-IPV-HB-Hib)
Study: 39385752
Drug: Pentavalent vaccine
Normalized name: rotavirus, live, pentavalent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent vaccine (DTwP-HB-Hib)
Study: 39386177
Drug: High-dose Tacrosolv
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Tacrosolv (5 µg tacrolimus/eye/day)
Study: 39386444
Drug: Neoadjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant endocrine therapy with letrozole
Study: 39386444
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (letrozole)
Study: 39387403
Drug: Other disease-modifying
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other disease-modifying antirheumatic drugs
Study: 39387441
Drug: Asciminib (oral),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asciminib (oral), dose-escalation in second-line treatment
Study: 39387441
Drug: Asciminib (oral),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asciminib (oral), dose-escalation in first-line treatment
Study: 39387766
Drug: Renin-angiotensin system
Normalized name: Renin-angiotensin system inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-angiotensin system inhibitor (RASi)
Study: 39389076
Drug: MVA-MERS-S vaccine
Normalized name: MVA-SARS-2-S
DrugBank: MVA-SARS-2-S (DB16432)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-MERS-S vaccine (10^8 PFU) administered intramuscularly in three doses at 28-day intervals
Study: 39389081
Drug: VIR-2218 200
Normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIR-2218 200 mg subcutaneously every 4 weeks (cohort 1)
Study: 39389081
Drug: VIR-2218 200
Normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 2)
Study: 39389081
Drug: VIR-2218 200
Normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 3)
Study: 39389081
Drug: VIR-2218 200
Normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 4)
Study: 39389081
Drug: VIR-2218 200
Normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 5)
Study: 39389081
Drug: VIR-2218 200
Normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 6)
Study: 39389081
Drug: VIR-2218 200
Normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIR-2218 200 mg subcutaneously every 4 weeks
Study: 39389599
Drug: Blood and
Normalized name: BLOOD AND RELATED PRODUCTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood and biological samples (plasma and saliva) collected during treatment
Study: 39390132
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bevacizumab-800CW
Study: 39390132
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg bevacizumab-800CW
Study: 39390228
Drug: Newly restored
Normalized name: Restone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly restored implant (PICF)
Study: 39390362
Drug: Wait-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list control group (maintained usual activity, received monthly health education talk)
Study: 39390398
Drug: COVID-19 mRNA
Normalized name: COVID-19 mRNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 mRNA booster vaccine
Study: 39390583
Drug: MIPD dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIPD dosing calculator for AUC-based dosing with extra sampling for therapeutic drug monitoring
Study: 39390760
Drug: White button
Normalized name: button mushroom extract
DrugBank: Cultivated mushroom (DB10544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White button mushroom (WBM) treatment
Study: 39390760
Drug: White button
Normalized name: button mushroom extract
DrugBank: Cultivated mushroom (DB10544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White button mushroom (WBM) tablets for 3 months
Study: 39392161
Drug: Protocolized intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Protocolized intervention pathway activated by high-risk scores; nurse-implemented uptitration of diuretic for 4 days
Study: 39392467
Drug: Low-load blood
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-load blood flow restriction exercise (BFRE) at 40% total arterial occlusion pressure, using 30-40% of 1-repetition maximum loads, conducted twice weekly for two weeks
Study: 39392616
Drug: Algorithm-based mobile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm-based mobile texting platform delivering 4 treatment modules (education and behavioral modification, cognitive behavioral therapy, pelvic floor physical therapy, guided mindfulness practices) and an automated weekly message over 6 weeks
Study: 39393045
Drug: IV natalizumab
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV natalizumab Q6W dosing
Study: 39393045
Drug: IV natalizumab
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV natalizumab Q4W dosing
Study: 39393045
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of Q6W vs Q4W dosing
Study: 39393084
Drug: 60-mg admilparant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-mg admilparant
Study: 39393084
Drug: 30-mg admilparant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-mg admilparant
Study: 39393528
Drug: Opioid-free anesthesia
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-free anesthesia (OFA) with sevoflurane-dexmedetomidine, continuous infusion of lidocaine and ketamine, and magnesium sulfate during induction
Study: 39393528
Drug: Opioid-sparing anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-sparing anesthesia (OSA) with sevoflurane-sufentanil boluses and continuous infusion of lidocaine
Study: 39393777
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy (±bevacizumab)
Study: 39393777
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy (±bevacizumab)
Study: 39393844
Drug: Allogeneic bone
Normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic bone marrow mesenchymal stromal cells (BM-MSCs) - 20 million cells via intradiscal injection
Study: 39393844
Drug: Sham placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham placebo injection
Study: 39394158
Drug: CR +
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CR + BWLT (12 weekly, group-based virtual sessions, followed by 12 weeks of follow-up support)
Study: 39395139
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care services (medication reconciliation, medication review, patient education)
Study: 39395230
Drug: SARS-CoV-2 mRNA
Normalized name: SARS-CoV-2 mRNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 mRNA vaccination (specific dosage and duration not mentioned)